片頭痛治療薬の世界市場

片頭痛治療薬の世界市場は2030年までに92億米ドルに到達

2023年に32億米ドルと推定される片頭痛治療薬の世界市場は、分析期間2023-2030年にCAGR 16.1%で成長し、2030年には92億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである急性治療は、CAGR 16.7%を記録し、分析期間終了時には72億米ドルに達すると予測されます。予防治療セグメントの成長率は、分析期間中CAGR 14.2%と推定されます。

米国市場は8億7,330万米ドルと推定、中国はCAGR21.6％で成長予測

米国の片頭痛治療薬市場は、2023年に8億7,330万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに22億米ドルの市場規模に達すると予測され、分析期間2023-2030年のCAGRは21.6%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ11.7%と13.6%と予測されています。欧州では、ドイツがCAGR約12.6%で成長すると予測されています。

世界の片頭痛治療薬市場- 主要動向と促進要因のまとめ

片頭痛治療薬は、しばしば吐き気、嘔吐、光や音に対する過敏症を伴う、激しい頭痛の再発を特徴とする衰弱性の神経症状である片頭痛の管理および治療に不可欠です。これらの薬剤は、片頭痛発作時の症状を緩和する急性治療と、発作の頻度や重症度を軽減する予防治療に大別されます。急性治療薬にはトリプタン系薬剤、エルゴタミン系薬剤、非ステロイド性抗炎症薬（NSAIDs）などがあり、予防治療薬にはβ遮断薬、抗けいれん薬、新しい分類のカルシトニン遺伝子関連ペプチド（CGRP）阻害薬などがあります。エレヌマブ、フレマネズマブ、ガルカネズマブなどのCGRP阻害薬は、片頭痛の病態生理学において重要な役割を果たすCGRP経路を標的とすることにより、片頭痛予防に革命をもたらしました。これらの標的治療薬が利用可能になったことで、従来の薬物療法では緩和が限られていた多くの片頭痛患者の生活の質が大幅に改善されました。

片頭痛治療薬の世界市場は、片頭痛の有病率の増加と、この症状が生活の質に与える影響に対する意識の高まりにより、急速に拡大しています。世界保健機関（WHO）によると、片頭痛は世界の身体障害の主要原因の一つであり、推定10億人が罹患しています。この高い有病率から、効果的な片頭痛管理戦略の必要性が強調され、この分野の研究開発に拍車がかかっています。製薬会社は、次世代のCGRP阻害剤や、有効性を高め副作用を軽減する併用療法など、新規の片頭痛治療薬の開発に多額の投資を行っています。さらに、モバイルアプリやウェアラブルデバイスを利用して片頭痛を監視・管理するデジタル治療薬の導入は、個別化された片頭痛治療における大きな進歩です。これらのデジタルツールにより、患者は症状、誘因、薬の使用状況を追跡できるようになり、より正確で効果的な治療計画が立てやすくなります。

片頭痛治療薬市場の成長は、医薬品開発における技術進歩、個別化医療に対する需要の高まり、慢性片頭痛の有病率の上昇など、いくつかの要因によってもたらされます。技術革新は、片頭痛の予防と治療を一変させたCGRP阻害剤など、より効果的で的を絞った治療法の開発につながった。また、個別化医療に対する需要の高まりも市場を後押ししており、患者は特定の遺伝的要因や生活様式に合わせた治療を求めています。さらに、世界人口のかなりの部分が罹患している慢性片頭痛の有病率の上昇が、効果的な片頭痛治療に対する大きな需要を生み出しています。新興市場におけるヘルスケア・インフラの拡大と、先進的な片頭痛治療へのアクセスの増加が、市場の成長をさらに促進しています。さらに、片頭痛とその治療法に関する認識と教育の高まりが、患者に医療支援を求める力を与え、片頭痛治療薬の需要を促進しています。これらの要因が総合的に片頭痛治療薬市場の堅調な成長に寄与しており、医学研究の継続的な進歩と世界中の片頭痛患者のニーズの進化を反映しています。

調査対象企業の例（全59件）

• Allergan PLC
• Amgen, Inc.
• Biohaven Pharmaceutical Holding Company Ltd.
• Eli Lilly and Company
• GlaxoSmithKline PLC
• Johnson & Johnson
• Pfizer, Inc.
• Teva Pharmaceutical Industries Ltd.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Migraine Drugs Market to Reach US$9.2 Billion by 2030

The global market for Migraine Drugs estimated at US$3.2 Billion in the year 2023, is expected to reach US$9.2 Billion by 2030, growing at a CAGR of 16.1% over the analysis period 2023-2030. Acute Treatment, one of the segments analyzed in the report, is expected to record a 16.7% CAGR and reach US$7.2 Billion by the end of the analysis period. Growth in the Preventive Treatment segment is estimated at 14.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$873.3 Million While China is Forecast to Grow at 21.6% CAGR

The Migraine Drugs market in the U.S. is estimated at US$873.3 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$2.2 Billion by the year 2030 trailing a CAGR of 21.6% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 11.7% and 13.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 12.6% CAGR.

Global Migraine Drugs Market - Key Trends and Drivers Summarized

Migraine drugs are critical in the management and treatment of migraines, a debilitating neurological condition characterized by intense, recurrent headaches often accompanied by nausea, vomiting, and sensitivity to light and sound. These medications are broadly categorized into acute treatments, which alleviate symptoms during a migraine attack, and preventive treatments, which reduce the frequency and severity of attacks. Acute treatments include triptans, ergotamines, and nonsteroidal anti-inflammatory drugs (NSAIDs), while preventive treatments encompass beta-blockers, anticonvulsants, and the newer class of calcitonin gene-related peptide (CGRP) inhibitors. CGRP inhibitors, such as erenumab, fremanezumab, and galcanezumab, have revolutionized migraine prevention by targeting the CGRP pathway, which plays a crucial role in migraine pathophysiology. The availability of these targeted therapies has significantly improved the quality of life for many migraine sufferers who previously found limited relief with traditional medications.

The global market for migraine drugs has expanded rapidly, driven by the increasing prevalence of migraines and the growing awareness of the condition's impact on quality of life. According to the World Health Organization, migraines are one of the leading causes of disability worldwide, affecting an estimated one billion people. This high prevalence has underscored the need for effective migraine management strategies and spurred research and development in this field. Pharmaceutical companies are investing heavily in the development of novel migraine therapies, including next-generation CGRP inhibitors and combination therapies that offer enhanced efficacy and reduced side effects. Additionally, the introduction of digital therapeutics, which utilize mobile apps and wearable devices to monitor and manage migraines, represents a significant advancement in personalized migraine care. These digital tools enable patients to track their symptoms, triggers, and medication usage, facilitating more precise and effective treatment plans.

The growth in the migraine drugs market is driven by several factors, including technological advancements in drug development, increasing demand for personalized medicine, and the rising prevalence of chronic migraines. Technological innovations have led to the development of more effective and targeted therapies, such as CGRP inhibitors, which have transformed migraine prevention and treatment. The increasing demand for personalized medicine has also propelled the market, as patients seek treatments tailored to their specific genetic and lifestyle factors. Additionally, the rising prevalence of chronic migraines, which affect a significant portion of the global population, has created a substantial demand for effective migraine treatments. The expansion of healthcare infrastructure in emerging markets and the growing accessibility of advanced migraine therapies have further fueled market growth. Furthermore, increased awareness and education about migraines and their treatment options have empowered patients to seek medical help, thereby driving the demand for migraine drugs. These factors collectively contribute to the robust growth of the migraine drugs market, reflecting the ongoing advancements in medical research and the evolving needs of migraine sufferers worldwide.

Select Competitors (Total 59 Featured) -

• Allergan PLC
• Amgen, Inc.
• Biohaven Pharmaceutical Holding Company Ltd.
• Eli Lilly and Company
• GlaxoSmithKline PLC
• Johnson & Johnson
• Pfizer, Inc.
• Teva Pharmaceutical Industries Ltd.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • Global Economic Update
  • Migraine Drugs - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Prevalence of Chronic Migraines Expands Addressable Market Opportunity
  • Advances in CGRP Inhibitors Propel Growth in Migraine Treatment
  • Increasing Demand for Personalized Medicine Spurs Adoption of Tailored Therapies
  • Innovations in Digital Therapeutics Strengthen Business Case for Migraine Management
  • Growing Awareness of Migraine Impact on Quality of Life Drives Market Expansion
  • Technological Innovations in Drug Delivery Systems Propel Growth
  • Introduction of Combination Therapies Accelerates Demand for Migraine Drugs
  • Increased Investment in Migraine Research and Development Spurs Market Innovation
  • Focus on Reducing Side Effects and Improving Efficacy Drives Adoption of New Therapies
  • Consumer Preference for Non-Pharmacological Treatments Throws the Spotlight on Alternative Therapies
  • Rising Healthcare Expenditure Sustains Growth in Migraine Drugs Market
  • Growth of Telemedicine and Remote Monitoring Expands Accessibility to Migraine Care
  • Focus on Long-Term Preventive Treatments Expands Addressable Market
  • Increasing Prevalence of Lifestyle-Related Triggers Strengthens Business Case for Migraine Therapies
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Migraine Drugs Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Migraine Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Migraine Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 4: World 16-Year Perspective for Migraine Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Acute Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Acute Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 7: World 16-Year Perspective for Acute Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Preventive Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Preventive Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 10: World 16-Year Perspective for Preventive Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Triptans by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Triptans by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 13: World 16-Year Perspective for Triptans by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Acetylcholine Inhibitors / Neurotoxins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Acetylcholine Inhibitors / Neurotoxins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 16: World 16-Year Perspective for Acetylcholine Inhibitors / Neurotoxins by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Ergot Alkaloids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Ergot Alkaloids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 19: World 16-Year Perspective for Ergot Alkaloids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for NSAIDs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 21: World Historic Review for NSAIDs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 22: World 16-Year Perspective for NSAIDs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Other Therapeutic Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Other Therapeutic Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 25: World 16-Year Perspective for Other Therapeutic Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 28: World 16-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Injectables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Injectables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 31: World 16-Year Perspective for Injectables by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Other Route of Administrations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Other Route of Administrations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 34: World 16-Year Perspective for Other Route of Administrations by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Migraine Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • TABLE 35: USA Recent Past, Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 36: USA Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 37: USA 16-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2014, 2024 & 2030
  • TABLE 38: USA Recent Past, Current & Future Analysis for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 39: USA Historic Review for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 40: USA 16-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes for the Years 2014, 2024 & 2030
  • TABLE 41: USA Recent Past, Current & Future Analysis for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 42: USA Historic Review for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 43: USA 16-Year Perspective for Migraine Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Route of Administrations for the Years 2014, 2024 & 2030
• CANADA
  • TABLE 44: Canada Recent Past, Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 45: Canada Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 46: Canada 16-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2014, 2024 & 2030
  • TABLE 47: Canada Recent Past, Current & Future Analysis for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 48: Canada Historic Review for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 49: Canada 16-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes for the Years 2014, 2024 & 2030
  • TABLE 50: Canada Recent Past, Current & Future Analysis for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 51: Canada Historic Review for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 52: Canada 16-Year Perspective for Migraine Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Route of Administrations for the Years 2014, 2024 & 2030
• JAPAN
  • Migraine Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • TABLE 53: Japan Recent Past, Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 54: Japan Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 55: Japan 16-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2014, 2024 & 2030
  • TABLE 56: Japan Recent Past, Current & Future Analysis for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 57: Japan Historic Review for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 58: Japan 16-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes for the Years 2014, 2024 & 2030
  • TABLE 59: Japan Recent Past, Current & Future Analysis for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 60: Japan Historic Review for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 61: Japan 16-Year Perspective for Migraine Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Route of Administrations for the Years 2014, 2024 & 2030
• CHINA
  • Migraine Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • TABLE 62: China Recent Past, Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 63: China Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 64: China 16-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2014, 2024 & 2030
  • TABLE 65: China Recent Past, Current & Future Analysis for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 66: China Historic Review for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 67: China 16-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes for the Years 2014, 2024 & 2030
  • TABLE 68: China Recent Past, Current & Future Analysis for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 69: China Historic Review for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 70: China 16-Year Perspective for Migraine Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Route of Administrations for the Years 2014, 2024 & 2030
• EUROPE
  • Migraine Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • TABLE 71: Europe Recent Past, Current & Future Analysis for Migraine Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 72: Europe Historic Review for Migraine Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 73: Europe 16-Year Perspective for Migraine Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
  • TABLE 74: Europe Recent Past, Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 75: Europe Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 76: Europe 16-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2014, 2024 & 2030
  • TABLE 77: Europe Recent Past, Current & Future Analysis for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 78: Europe Historic Review for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 79: Europe 16-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes for the Years 2014, 2024 & 2030
  • TABLE 80: Europe Recent Past, Current & Future Analysis for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 81: Europe Historic Review for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 82: Europe 16-Year Perspective for Migraine Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Route of Administrations for the Years 2014, 2024 & 2030
• FRANCE
  • Migraine Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • TABLE 83: France Recent Past, Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 84: France Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 85: France 16-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2014, 2024 & 2030
  • TABLE 86: France Recent Past, Current & Future Analysis for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 87: France Historic Review for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 88: France 16-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes for the Years 2014, 2024 & 2030
  • TABLE 89: France Recent Past, Current & Future Analysis for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 90: France Historic Review for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 91: France 16-Year Perspective for Migraine Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Route of Administrations for the Years 2014, 2024 & 2030
• GERMANY
  • Migraine Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • TABLE 92: Germany Recent Past, Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 93: Germany Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 94: Germany 16-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2014, 2024 & 2030
  • TABLE 95: Germany Recent Past, Current & Future Analysis for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 96: Germany Historic Review for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 97: Germany 16-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes for the Years 2014, 2024 & 2030
  • TABLE 98: Germany Recent Past, Current & Future Analysis for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 99: Germany Historic Review for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 100: Germany 16-Year Perspective for Migraine Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Route of Administrations for the Years 2014, 2024 & 2030
• ITALY
  • TABLE 101: Italy Recent Past, Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 102: Italy Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 103: Italy 16-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2014, 2024 & 2030
  • TABLE 104: Italy Recent Past, Current & Future Analysis for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 105: Italy Historic Review for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 106: Italy 16-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes for the Years 2014, 2024 & 2030
  • TABLE 107: Italy Recent Past, Current & Future Analysis for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 108: Italy Historic Review for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 109: Italy 16-Year Perspective for Migraine Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Route of Administrations for the Years 2014, 2024 & 2030
• UNITED KINGDOM
  • Migraine Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • TABLE 110: UK Recent Past, Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 111: UK Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 112: UK 16-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2014, 2024 & 2030
  • TABLE 113: UK Recent Past, Current & Future Analysis for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 114: UK Historic Review for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 115: UK 16-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes for the Years 2014, 2024 & 2030
  • TABLE 116: UK Recent Past, Current & Future Analysis for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 117: UK Historic Review for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 118: UK 16-Year Perspective for Migraine Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Route of Administrations for the Years 2014, 2024 & 2030
• SPAIN
  • TABLE 119: Spain Recent Past, Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 120: Spain Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 121: Spain 16-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2014, 2024 & 2030
  • TABLE 122: Spain Recent Past, Current & Future Analysis for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 123: Spain Historic Review for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 124: Spain 16-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes for the Years 2014, 2024 & 2030
  • TABLE 125: Spain Recent Past, Current & Future Analysis for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 126: Spain Historic Review for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 127: Spain 16-Year Perspective for Migraine Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Route of Administrations for the Years 2014, 2024 & 2030
• RUSSIA
  • TABLE 128: Russia Recent Past, Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 129: Russia Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 130: Russia 16-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2014, 2024 & 2030
  • TABLE 131: Russia Recent Past, Current & Future Analysis for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 132: Russia Historic Review for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 133: Russia 16-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes for the Years 2014, 2024 & 2030
  • TABLE 134: Russia Recent Past, Current & Future Analysis for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 135: Russia Historic Review for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 136: Russia 16-Year Perspective for Migraine Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Route of Administrations for the Years 2014, 2024 & 2030
• REST OF EUROPE
  • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 138: Rest of Europe Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 139: Rest of Europe 16-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2014, 2024 & 2030
  • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 141: Rest of Europe Historic Review for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 142: Rest of Europe 16-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes for the Years 2014, 2024 & 2030
  • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 144: Rest of Europe Historic Review for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 145: Rest of Europe 16-Year Perspective for Migraine Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Route of Administrations for the Years 2014, 2024 & 2030
• ASIA-PACIFIC
  • Migraine Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Migraine Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 147: Asia-Pacific Historic Review for Migraine Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 148: Asia-Pacific 16-Year Perspective for Migraine Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
  • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 150: Asia-Pacific Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 151: Asia-Pacific 16-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2014, 2024 & 2030
  • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 153: Asia-Pacific Historic Review for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 154: Asia-Pacific 16-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes for the Years 2014, 2024 & 2030
  • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 156: Asia-Pacific Historic Review for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 157: Asia-Pacific 16-Year Perspective for Migraine Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Route of Administrations for the Years 2014, 2024 & 2030
• AUSTRALIA
  • Migraine Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
  • TABLE 158: Australia Recent Past, Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 159: Australia Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 160: Australia 16-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2014, 2024 & 2030
  • TABLE 161: Australia Recent Past, Current & Future Analysis for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 162: Australia Historic Review for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 163: Australia 16-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes for the Years 2014, 2024 & 2030
  • TABLE 164: Australia Recent Past, Current & Future Analysis for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 165: Australia Historic Review for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 166: Australia 16-Year Perspective for Migraine Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Route of Administrations for the Years 2014, 2024 & 2030
• INDIA
  • Migraine Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
  • TABLE 167: India Recent Past, Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 168: India Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 169: India 16-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2014, 2024 & 2030
  • TABLE 170: India Recent Past, Current & Future Analysis for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 171: India Historic Review for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 172: India 16-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes for the Years 2014, 2024 & 2030
  • TABLE 173: India Recent Past, Current & Future Analysis for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 174: India Historic Review for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 175: India 16-Year Perspective for Migraine Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Route of Administrations for the Years 2014, 2024 & 2030
• SOUTH KOREA
  • TABLE 176: South Korea Recent Past, Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 177: South Korea Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 178: South Korea 16-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2014, 2024 & 2030
  • TABLE 179: South Korea Recent Past, Current & Future Analysis for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 180: South Korea Historic Review for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 181: South Korea 16-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes for the Years 2014, 2024 & 2030
  • TABLE 182: South Korea Recent Past, Current & Future Analysis for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 183: South Korea Historic Review for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 184: South Korea 16-Year Perspective for Migraine Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Route of Administrations for the Years 2014, 2024 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 186: Rest of Asia-Pacific Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 187: Rest of Asia-Pacific 16-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2014, 2024 & 2030
  • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 189: Rest of Asia-Pacific Historic Review for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 190: Rest of Asia-Pacific 16-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes for the Years 2014, 2024 & 2030
  • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 192: Rest of Asia-Pacific Historic Review for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 193: Rest of Asia-Pacific 16-Year Perspective for Migraine Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Route of Administrations for the Years 2014, 2024 & 2030
• LATIN AMERICA
  • Migraine Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
  • TABLE 194: Latin America Recent Past, Current & Future Analysis for Migraine Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 195: Latin America Historic Review for Migraine Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 196: Latin America 16-Year Perspective for Migraine Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
  • TABLE 197: Latin America Recent Past, Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 198: Latin America Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 199: Latin America 16-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2014, 2024 & 2030
  • TABLE 200: Latin America Recent Past, Current & Future Analysis for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 201: Latin America Historic Review for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 202: Latin America 16-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes for the Years 2014, 2024 & 2030
  • TABLE 203: Latin America Recent Past, Current & Future Analysis for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 204: Latin America Historic Review for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 205: Latin America 16-Year Perspective for Migraine Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Route of Administrations for the Years 2014, 2024 & 2030
• ARGENTINA
  • TABLE 206: Argentina Recent Past, Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 207: Argentina Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 208: Argentina 16-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2014, 2024 & 2030
  • TABLE 209: Argentina Recent Past, Current & Future Analysis for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 210: Argentina Historic Review for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 211: Argentina 16-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes for the Years 2014, 2024 & 2030
  • TABLE 212: Argentina Recent Past, Current & Future Analysis for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 213: Argentina Historic Review for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 214: Argentina 16-Year Perspective for Migraine Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Route of Administrations for the Years 2014, 2024 & 2030
• BRAZIL
  • TABLE 215: Brazil Recent Past, Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 216: Brazil Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 217: Brazil 16-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2014, 2024 & 2030
  • TABLE 218: Brazil Recent Past, Current & Future Analysis for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 219: Brazil Historic Review for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 220: Brazil 16-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes for the Years 2014, 2024 & 2030
  • TABLE 221: Brazil Recent Past, Current & Future Analysis for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 222: Brazil Historic Review for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 223: Brazil 16-Year Perspective for Migraine Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Route of Administrations for the Years 2014, 2024 & 2030
• MEXICO
  • TABLE 224: Mexico Recent Past, Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 225: Mexico Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 226: Mexico 16-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2014, 2024 & 2030
  • TABLE 227: Mexico Recent Past, Current & Future Analysis for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 228: Mexico Historic Review for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 229: Mexico 16-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes for the Years 2014, 2024 & 2030
  • TABLE 230: Mexico Recent Past, Current & Future Analysis for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 231: Mexico Historic Review for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 232: Mexico 16-Year Perspective for Migraine Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Route of Administrations for the Years 2014, 2024 & 2030
• REST OF LATIN AMERICA
  • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 234: Rest of Latin America Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 235: Rest of Latin America 16-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2014, 2024 & 2030
  • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 237: Rest of Latin America Historic Review for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 238: Rest of Latin America 16-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes for the Years 2014, 2024 & 2030
  • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 240: Rest of Latin America Historic Review for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 241: Rest of Latin America 16-Year Perspective for Migraine Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Route of Administrations for the Years 2014, 2024 & 2030
• MIDDLE EAST
  • Migraine Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
  • TABLE 242: Middle East Recent Past, Current & Future Analysis for Migraine Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 243: Middle East Historic Review for Migraine Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 244: Middle East 16-Year Perspective for Migraine Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
  • TABLE 245: Middle East Recent Past, Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 246: Middle East Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 247: Middle East 16-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2014, 2024 & 2030
  • TABLE 248: Middle East Recent Past, Current & Future Analysis for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 249: Middle East Historic Review for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 250: Middle East 16-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes for the Years 2014, 2024 & 2030
  • TABLE 251: Middle East Recent Past, Current & Future Analysis for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 252: Middle East Historic Review for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 253: Middle East 16-Year Perspective for Migraine Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Route of Administrations for the Years 2014, 2024 & 2030
• IRAN
  • TABLE 254: Iran Recent Past, Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 255: Iran Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 256: Iran 16-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2014, 2024 & 2030
  • TABLE 257: Iran Recent Past, Current & Future Analysis for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 258: Iran Historic Review for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 259: Iran 16-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes for the Years 2014, 2024 & 2030
  • TABLE 260: Iran Recent Past, Current & Future Analysis for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 261: Iran Historic Review for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 262: Iran 16-Year Perspective for Migraine Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Route of Administrations for the Years 2014, 2024 & 2030
• ISRAEL
  • TABLE 263: Israel Recent Past, Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 264: Israel Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 265: Israel 16-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2014, 2024 & 2030
  • TABLE 266: Israel Recent Past, Current & Future Analysis for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 267: Israel Historic Review for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 268: Israel 16-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes for the Years 2014, 2024 & 2030
  • TABLE 269: Israel Recent Past, Current & Future Analysis for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 270: Israel Historic Review for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 271: Israel 16-Year Perspective for Migraine Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Route of Administrations for the Years 2014, 2024 & 2030
• SAUDI ARABIA
  • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 273: Saudi Arabia Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 274: Saudi Arabia 16-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2014, 2024 & 2030
  • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 276: Saudi Arabia Historic Review for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 277: Saudi Arabia 16-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes for the Years 2014, 2024 & 2030
  • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 279: Saudi Arabia Historic Review for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 280: Saudi Arabia 16-Year Perspective for Migraine Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Route of Administrations for the Years 2014, 2024 & 2030
• UNITED ARAB EMIRATES
  • TABLE 281: UAE Recent Past, Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 282: UAE Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 283: UAE 16-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2014, 2024 & 2030
  • TABLE 284: UAE Recent Past, Current & Future Analysis for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 285: UAE Historic Review for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 286: UAE 16-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes for the Years 2014, 2024 & 2030
  • TABLE 287: UAE Recent Past, Current & Future Analysis for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 288: UAE Historic Review for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 289: UAE 16-Year Perspective for Migraine Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Route of Administrations for the Years 2014, 2024 & 2030
• REST OF MIDDLE EAST
  • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 291: Rest of Middle East Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 292: Rest of Middle East 16-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2014, 2024 & 2030
  • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 294: Rest of Middle East Historic Review for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 295: Rest of Middle East 16-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes for the Years 2014, 2024 & 2030
  • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 297: Rest of Middle East Historic Review for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 298: Rest of Middle East 16-Year Perspective for Migraine Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Route of Administrations for the Years 2014, 2024 & 2030
• AFRICA
  • Migraine Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
  • TABLE 299: Africa Recent Past, Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 300: Africa Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 301: Africa 16-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2014, 2024 & 2030
  • TABLE 302: Africa Recent Past, Current & Future Analysis for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 303: Africa Historic Review for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 304: Africa 16-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes for the Years 2014, 2024 & 2030
  • TABLE 305: Africa Recent Past, Current & Future Analysis for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 306: Africa Historic Review for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 307: Africa 16-Year Perspective for Migraine Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Route of Administrations for the Years 2014, 2024 & 2030

IV. COMPETITION